Cellectis CLLS
NASDAQ CLLS
$1.47 -0.04 (-2.61%)
As of: Oct 1, 2026 · 10:41 AM EDT

Cellectis (CLLS) Current Deferred Tax Assets (2024)

Updated

Cellectis (CLLS) reported Current Deferred Tax Assets of $710,000 for Q2 2024, up 73.6% from the prior quarter.

Analysis

Cellectis (CLLS) Current Deferred Tax Assets (2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Cellectis 151.51 Mn -601.88 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2024 710,000.00
Mar 31, 2024 409,000.00
API Access

Cellectis Current Deferred Tax Assets API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-tax-assets&ticker=CLLS&period=max&api_key=YOUR_API_KEY